North America Oral Antibiotics Market Outlook, 2030

The North America oral antibiotics market will grow by 2%, driven by increased antibiotic resistance and pharmaceutical R&D.

The North American oral antibiotics market is a significant segment within the broader pharmaceutical industry, experiencing steady growth driven by a confluence of factors. The increasing prevalence of bacterial infections, coupled with a rising geriatric population susceptible to such infections, fuels the demand for effective oral antibiotic therapies. Furthermore, the convenience and ease of administration associated with oral medications make them a preferred choice for both patients and healthcare providers, contributing to the market's expansion. Advancements in pharmaceutical research and development have led to the introduction of novel oral antibiotic formulations with improved efficacy and safety profiles, further propelling market growth. However, the market also faces challenges, including the growing concern of antibiotic resistance, which necessitates the development of new drugs and responsible antibiotic stewardship practices. Additionally, regulatory hurdles and pricing pressures can impact market dynamics. Despite these challenges, the North American oral antibiotics market is poised for continued growth, driven by the ongoing need for effective treatments for bacterial infections and the development of innovative drug therapies.

North America oral antibiotics market is expected to grow by 2.8% annually in the forecast period and reach $6,122.9 million by 2030 driven by rising complications associated with COVID-19 epidemic, development of innovative antibiotics, and growing healthcare expenditure. The North American oral antibiotics market is dynamic, shaped by a confluence of trends, drivers, and programs. A key trend is the escalating challenge of antimicrobial resistance (AMR), compelling the development of new antibiotics and promoting responsible antibiotic stewardship. This necessitates innovative research and development, including exploring alternative therapies and diagnostic tools to guide antibiotic use. The market is also witnessing a shift towards narrow-spectrum antibiotics, which target specific bacteria, minimizing the risk of resistance development compared to broad-spectrum antibiotics. Several factors drive the market. The rising prevalence of bacterial infections, especially in an aging population, fuels demand for effective treatments. Increased healthcare expenditure in North America supports access to medications and advanced therapies. Growing awareness about infectious diseases and the importance of timely treatment also contributes to market growth. Trade programs and initiatives play a crucial role. Governments and healthcare organizations are implementing antibiotic stewardship programs to promote judicious use of antibiotics, curbing resistance and ensuring their long-term effectiveness. Public health campaigns educate healthcare providers and the public about responsible antibiotic use. Regulatory agencies like the FDA expedite the approval process for novel antibiotics to address unmet medical needs. International collaborations and partnerships facilitate research and development efforts, fostering innovation in this critical therapeutic area.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


The North American oral antibiotics market is segmented by drug class, each with distinct characteristics and applications. Penicillins, a cornerstone of antibiotic therapy, remain widely used due to their efficacy against many bacterial infections, though resistance is a growing concern. They are often the first-line treatment for various infections, particularly those caused by gram-positive bacteria. Cephalosporins, a broader class, are categorized into generations, each with varying spectra of activity. Later generations often target more resistant organisms and gram-negative bacteria, expanding their clinical utility. Macrolides, known for their effectiveness against atypical bacteria, are frequently used to treat respiratory tract infections and are a suitable alternative for patients with penicillin allergies. Tetracyclines, while effective against a range of infections, have seen decreased use due to concerns about long-term side effects and increasing resistance. However, they retain a niche in treating certain conditions like acne and some sexually transmitted infections. Fluoroquinolones, potent broad-spectrum antibiotics, are reserved for specific infections due to the risk of serious adverse events, including tendon rupture and peripheral neuropathy. Their use is carefully monitored and restricted to situations where other options are unsuitable. Sulfonamides, often combined with other drugs, are effective against certain urinary tract infections and other bacterial infections. Lincosamides, such as clindamycin, are used to treat serious infections, particularly those involving anaerobic bacteria. Glycopeptides, primarily vancomycin, are crucial for treating infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant gram-positive bacteria. This class is usually administered intravenously but oral formulations exist for specific indications like Clostridium difficile infection. The market share of each drug class is influenced by factors such as the prevalence of specific infections, the emergence of resistance, and the availability of newer antibiotics. Ongoing research and development efforts focus on developing new antibiotics within existing classes and exploring novel drug classes to combat the growing threat of antibiotic resistance and address unmet medical needs. The choice of antibiotic class depends on the pathogen causing the infection, its susceptibility profile, the patient's condition, and other factors considered by healthcare professionals.

The North American oral antibiotics market can be segmented by mechanism of action, reflecting the diverse ways these drugs target bacterial cells. Cell wall synthesis inhibitors interfere with the construction of the bacterial cell wall, a vital structure for bacterial survival. This class includes penicillins, cephalosporins, and carbapenems. They work by binding to specific proteins, preventing the cross-linking of peptidoglycans, the building blocks of the cell wall, ultimately leading to bacterial lysis. Protein synthesis inhibitors target bacterial ribosomes, the cellular machinery responsible for protein production. Since bacterial ribosomes differ structurally from human ribosomes, these antibiotics can selectively inhibit bacterial protein synthesis without harming human cells. This class includes macrolides, tetracyclines, aminoglycosides, and lincosamides. They bind to different ribosomal subunits, disrupting various stages of protein synthesis, such as initiation, elongation, or translocation. DNA replication inhibitors interfere with bacterial DNA replication, preventing the bacteria from multiplying. Fluoroquinolones, a prominent example, target bacterial topoisomerases, enzymes essential for DNA unwinding and replication. By inhibiting these enzymes, fluoroquinolones disrupt DNA replication, leading to bacterial death. Metabolic pathway inhibitors target specific metabolic pathways essential for bacterial survival. Sulfonamides, for instance, interfere with the synthesis of folic acid, a crucial nutrient for bacterial growth. By blocking folic acid production, sulfonamides inhibit bacterial metabolism and growth. RNA synthesis inhibitors, such as rifampin, block bacterial RNA polymerase, the enzyme responsible for transcribing DNA into RNA. This prevents the bacteria from producing essential proteins, ultimately leading to bacterial death. Cell membrane disruptors, like polymyxins, disrupt the integrity of the bacterial cell membrane, causing leakage of cellular contents and bacterial death. This class is often reserved for treating infections caused by multidrug-resistant bacteria due to their potential toxicity. The specific mechanism of action of an antibiotic determines its spectrum of activity, its effectiveness against different types of bacteria. Understanding the mechanism of action is crucial for selecting the appropriate antibiotic for a particular infection and for developing new antibiotics that can overcome resistance mechanisms. The emergence of antibiotic resistance often involves mutations in the bacterial targets of these drugs, rendering them ineffective. Therefore, ongoing research and development efforts focus on discovering new antibiotics with novel mechanisms of action to combat the growing threat of antibiotic resistance and ensure effective treatment of bacterial infections.

The North American oral antibiotics market can be segmented by drug origin, categorizing antibiotics based on their source and method of discovery. Natural antibiotics are derived from natural sources, primarily microorganisms like bacteria and fungi. Many of the earliest and still widely used antibiotics, such as penicillins and cephalosporins, fall into this category. These compounds are often produced by microorganisms as a defense mechanism against other microbes. Researchers isolate and purify these natural products to create pharmaceutical antibiotics. While natural antibiotics have been incredibly successful, the search for new natural antibiotics has become more challenging as many readily accessible sources have been explored. Semi-synthetic antibiotics are derived from natural antibiotics that have been chemically modified to enhance their properties. These modifications can improve the drug's efficacy, broaden its spectrum of activity, increase its stability, or reduce its side effects. Many modern antibiotics are semi-synthetic derivatives of natural compounds. For example, various penicillins and cephalosporins are created by modifying the basic structure of naturally occurring penicillins and cephalosporins. This approach allows scientists to create antibiotics that are more effective against resistant bacteria or have improved pharmacokinetic properties. Synthetic antibiotics are entirely synthesized in the laboratory through chemical processes. These antibiotics are not derived from natural sources. The development of synthetic antibiotics allows for greater flexibility in drug design and can lead to the creation of novel compounds with unique mechanisms of action. Fluoroquinolones and sulfonamides are examples of synthetic antibiotics. Synthetic approaches can also be more efficient and cost-effective for manufacturing certain antibiotics compared to isolating and purifying natural products. Biotechnology-derived antibiotics are produced using recombinant DNA technology and other advanced biotechnological methods. This approach allows for the production of complex antibiotic molecules that may be difficult or impossible to synthesize chemically. Biotechnology-derived antibiotics may include monoclonal antibodies that target specific bacterial components or other novel therapeutic proteins with antibacterial activity. The drug's origin influences the complexity of the manufacturing process, the potential for structural modifications, and the overall cost of production. While natural and semi-synthetic antibiotics have historically dominated the market, the development of synthetic and biotechnology-derived antibiotics is becoming increasingly important in the face of rising antibiotic resistance and the need for new and innovative therapies. The future of antibiotic development likely involves a combination of approaches, including exploring new natural sources, modifying existing antibiotics, and designing novel synthetic and biotechnology-derived compounds.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant




The North American oral antibiotics market is experiencing steady growth, driven by a confluence of factors including the rising prevalence of infectious diseases, a growing geriatric population more susceptible to infections, and increasing awareness about the importance of effective treatment. The market is segmented by drug class, spectrum of activity, and application. Beta-lactams, including penicillins and cephalosporins, dominate the market due to their broad-spectrum activity and established safety profile. However, the increasing prevalence of antibiotic resistance is fueling demand for newer classes of antibiotics, such as quinolones and macrolides. The market is also witnessing a shift towards broad-spectrum antibiotics, which are effective against a wide range of bacterial infections. This trend is attributed to the increasing complexity of infections and the need for prompt and effective treatment. In terms of application, the respiratory tract infections segment holds the largest share, owing to the high incidence of common cold, flu, and pneumonia. The urinary tract infections and skin infections segments are also significant contributors to the market growth. The North American oral antibiotics market is characterized by the presence of several established players, as well as emerging companies focusing on the development of novel antibiotics. The market is highly competitive, with companies vying for market share through product innovation, strategic collaborations, and aggressive marketing campaigns. Despite the growth prospects, the market faces challenges such as stringent regulatory requirements, pricing pressures, and the need for continuous research and development to combat antibiotic resistance. Nevertheless, the increasing burden of infectious diseases and the growing demand for effective treatment options are expected to sustain the growth of the North American oral antibiotics market in the coming years.

The North American oral antibiotics market is segmented by application into several key areas, each addressing a specific category of bacterial infections. The largest segment is respiratory tract infections (RTIs), encompassing a wide range of conditions like pneumonia, bronchitis, sinusitis, and pharyngitis. The high prevalence of these infections, especially during cold and flu seasons, drives the significant demand for oral antibiotics. Urinary tract infections (UTIs) form another substantial segment, particularly common among women. The ease of oral administration makes antibiotics a preferred treatment option for uncomplicated UTIs. Skin and soft tissue infections (SSTIs) represent a significant portion of the market, including conditions like cellulitis, abscesses, and wound infections. Oral antibiotics are often used for mild to moderate SSTIs, while more severe cases may require intravenous treatment. Dental infections also contribute to the market, with oral antibiotics used to treat abscesses, gum infections, and infections following dental procedures. Other applications include gastrointestinal infections, ear infections, and sexually transmitted infections. The diversity of bacterial infections across various body systems necessitates a wide range of oral antibiotic options to ensure effective treatment.

The North American oral antibiotics market is segmented by drug type into several key classes, each with distinct mechanisms of action and bacterial targets. Beta-lactams are the most widely used, encompassing penicillins (like amoxicillin) and cephalosporins (like cephalexin). They work by interfering with bacterial cell wall synthesis. Macrolides, such as azithromycin, are effective against a range of infections, particularly respiratory and skin infections, by inhibiting bacterial protein synthesis. Tetracyclines, like doxycycline, also target protein synthesis and are used for various infections, including acne and some sexually transmitted diseases. Quinolones, such as ciprofloxacin, interfere with bacterial DNA replication and are commonly used for urinary tract and respiratory infections. However, their use is increasingly restricted due to concerns about side effects and antibiotic resistance. Other classes include sulfonamides, which inhibit bacterial folic acid synthesis, and lincosamides, which also target protein synthesis. The choice of antibiotic depends on the type of infection, the bacteria causing it, and factors like patient allergies and local resistance patterns.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval


The North American oral antibiotics market is segmented by region into the United States and Canada, with the United States holding a significant majority of the market share. This dominance is attributed to several factors, including a large population base, a well-developed healthcare infrastructure, and high healthcare expenditure. The US also has a high prevalence of infectious diseases, such as respiratory tract infections and urinary tract infections, which contributes to the demand for oral antibiotics. Additionally, the presence of a large number of established pharmaceutical companies and research institutions in the US further fuels market growth. Canada, on the other hand, holds a smaller share of the market due to its smaller population and healthcare system. However, the Canadian market is also witnessing steady growth, driven by factors such as an aging population and increasing awareness about infectious diseases. Both the US and Canada are characterized by a high prevalence of antibiotic resistance, which is driving the demand for newer and more effective antibiotics. The regulatory landscape in both countries is stringent, with regulatory agencies like the FDA in the US and Health Canada ensuring the safety and efficacy of antibiotics.

Table of Contents

  • 1 Introduction 7
  • 1.1 Industry Definition and Research Scope 7
  • 1.1.1 Industry Definition 7
  • 1.1.2 Research Scope 8
  • 1.2 Research Methodology 11
  • 1.2.1 Overview of Market Research Methodology 11
  • 1.2.2 Market Assumption 12
  • 1.2.3 Secondary Data 12
  • 1.2.4 Primary Data 12
  • 1.2.5 Data Filtration and Model Design 14
  • 1.2.6 Market Size/Share Estimation 15
  • 1.2.7 Research Limitations 16
  • 1.3 Executive Summary 17
  • 2 Market Overview and Dynamics 20
  • 2.1 Market Size and Forecast 20
  • 2.1.1 Impact of COVID-19 on the Market 21
  • 2.2 Major Growth Drivers 23
  • 2.3 Market Restraints and Challenges 27
  • 2.4 Emerging Opportunities and Market Trends 30
  • 2.5 Porter’s Fiver Forces Analysis 34
  • 3 Segmentation of North America Market by Drug Class 38
  • 3.1 Market Overview by Drug Class 38
  • 3.2 Cephalosporin 40
  • 3.3 Penicillin 42
  • 3.4 Macrolides 43
  • 3.5 Tetracycline 44
  • 3.6 Quinolones 45
  • 3.7 Sulfonamides 46
  • 3.8 Aminoglycosides 47
  • 3.9 Other Drug Classes 48
  • 4 Segmentation of North America Market by Action Mechanism 49
  • 4.1 Market Overview by Action Mechanism 49
  • 4.2 Cell Wall Synthesis Inhibitors 51
  • 4.3 Mycolic Acid Inhibitors 52
  • 4.4 RNA Synthesis Inhibitors 53
  • 4.5 DNA Synthesis Inhibitors 54
  • 4.6 Protein Synthesis Inhibitors 55
  • 4.7 Other Mechanisms 56
  • 5 Segmentation of North America Market by Drug Origin 57
  • 5.1 Market Overview by Drug Origin 57
  • 5.2 Natural Antibiotics 59
  • 5.3 Semi-synthetic Antibiotics 60
  • 5.4 Synthetic Antibiotics 61
  • 6 Segmentation of North America Market by Activity Spectrum 62
  • 6.1 Market Overview by Activity Spectrum 62
  • 6.2 Broad-spectrum Antibiotics 64
  • 6.3 Narrow-spectrum Antibiotics 65
  • 7 Segmentation of North America Market by Application 66
  • 7.1 Market Overview by Application 66
  • 7.2 Urinary Tract Infections (UTIS) 68
  • 7.3 Dental Infections 69
  • 7.3.1 Monotherapies for Dental Infections 70
  • 7.3.2 Combined Therapies for Dental Infections 71
  • 7.4 Respiratory Tract Infections (RTIS) 72
  • 7.4.1 Upper Respiratory Tract Infections (URTI) 73
  • 7.4.2 Lower Respiratory Tract Infections (LRTIs) 74
  • 7.5 Other Applications 75
  • 8 Segmentation of North America Market by Drug Type 76
  • 8.1 Market Overview by Drug Type 76
  • 8.2 Brand Antibiotics 78
  • 8.3 Generic Antibiotics 79
  • 9 North America Market 2019-2030 by Country 80
  • 9.1 Overview of North America Market 80
  • 9.2 U.S. 83
  • 9.3 Canada 87
  • 9.4 Mexico 89
  • 10 Competitive Landscape 91
  • 10.1 Overview of Key Vendors 91
  • 10.2 New Product Launch, Partnership, Investment, and M&A 94
  • 10.3 Company Profiles 95
  • Abbott Laboratories 95
  • Astellas Pharma 97
  • AstraZeneca Plc 98
  • Bayer AG 99
  • Bristol Myers Squibb Company 100
  • Cipla Inc. 101
  • Dr. Reddy’s Laboratories Ltd. 102
  • Eli Lilly and Company 103
  • F. Hoffmann-La Roche Ltd. 104
  • Gilead Sciences, Inc. 105
  • GlaxoSmithKline plc. 106
  • Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) 107
  • Mayne Pharma Group Ltd. 108
  • MELINTA THERAPEUTICS, INC. 109
  • Merck KGaA 110
  • Novartis AG 111
  • Pfizer Inc. 112
  • Sanofi 113
  • Sun Pharmaceutical Industries Ltd. 114
  • 11 Investing in North America Market: Risk Assessment and Management 115
  • 11.1 Risk Evaluation of North America Market 115
  • 11.2 Critical Success Factors (CSFs) 118
  • Related Reports and Products 121

Table 1. Snapshot of Asia Pacific Oncology Informatics Market, 2019-2030 18
Table 2. Main Product Trends and Market Opportunities in Asia Pacific Oncology Informatics Market 29
Table 3. Asia Pacific Oncology Informatics Market by Product Type, 2019-2030, $ mn 37
Table 4. Key Products and EHR Vendors 40
Table 5. Key Products and PHM Vendors 42
Table 6. Key Products and CDSS Vendors 44
Table 7. Key Products and DDDI Vendors 46
Table 8. Asia Pacific Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 50
Table 9. Asia Pacific Oncology Informatics Market by Application, 2019-2030, $ mn 56
Table 10. Asia Pacific Oncology Informatics Market by End User, 2019-2030, $ mn 62
Table 11. APAC Oncology Informatics Market by Country, 2019-2030, $ mn 70
Table 12. Japan Oncology Informatics Market by Product Type, 2019-2030, $ mn 74
Table 13. Japan Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 74
Table 14. Japan Oncology Informatics Market by End User, 2019-2030, $ mn 74
Table 15. China Oncology Informatics Market by Product Type, 2019-2030, $ mn 76
Table 16. China Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 76
Table 17. China Oncology Informatics Market by End User, 2019-2030, $ mn 76
Table 18. Australia Oncology Informatics Market by Product Type, 2019-2030, $ mn 78
Table 19. Australia Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 78
Table 20. Australia Oncology Informatics Market by End User, 2019-2030, $ mn 78
Table 21. India Oncology Informatics Market by Product Type, 2019-2030, $ mn 80
Table 22. India Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 80
Table 23. India Oncology Informatics Market by End User, 2019-2030, $ mn 80
Table 24. South Korea Oncology Informatics Market by Product Type, 2019-2030, $ mn 82
Table 25. South Korea Oncology Informatics Market by Cancer Type, 2019-2030, $ mn 82
Table 26. South Korea Oncology Informatics Market by End User, 2019-2030, $ mn 82
Table 27. Oncology Informatics Market in Rest of APAC by Country, 2019-2030, $ mn 84
Table 28. Cerner Corporation: Company Snapshot 89
Table 29. Cerner Corporation: Business Segmentation 89
Table 30. Cerner Corporation: Product Portfolio 90
Table 31. Cerner Corporation: Revenue, 2016-2018, $ mn 90
Table 32. Cerner Corporation: Recent Developments 90
Table 33. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030 108
Table 34. Critical Success Factors and Key Takeaways 111

Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. North America Oral Antibiotics Market, 2019-2030, $ mn 20
Figure 6. Impact of COVID-19 on Business 21
Figure 7. Primary Drivers and Impact Factors of North America Oral Antibiotics Market 23
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 26
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 26
Figure 10. Primary Restraints and Impact Factors of North America Oral Antibiotics Market 27
Figure 11. Investment Opportunity Analysis 31
Figure 12. Porter’s Fiver Forces Analysis of North America Oral Antibiotics Market 34
Figure 13. Breakdown of North America Oral Antibiotics Market by Drug Class, 2019-2030, % of Revenue 39
Figure 14. North America Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%) 39
Figure 15. North America Oral Antibiotics Market: Cephalosporin, 2019-2030, $ mn 40
Figure 16. North America Oral Antibiotics Market: Penicillin, 2019-2030, $ mn 42
Figure 17. North America Oral Antibiotics Market: Macrolides, 2019-2030, $ mn 43
Figure 18. North America Oral Antibiotics Market: Tetracycline, 2019-2030, $ mn 44
Figure 19. North America Oral Antibiotics Market: Quinolones, 2019-2030, $ mn 45
Figure 20. North America Oral Antibiotics Market: Sulfonamides, 2019-2030, $ mn 46
Figure 21. North America Oral Antibiotics Market: Aminoglycosides, 2019-2030, $ mn 47
Figure 22. North America Oral Antibiotics Market: Other Drug Classes, 2019-2030, $ mn 48
Figure 23. Breakdown of North America Oral Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue 50
Figure 24. North America Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%) 50
Figure 25. North America Oral Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn 51
Figure 26. North America Oral Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn 52
Figure 27. North America Oral Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn 53
Figure 28. North America Oral Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn 54
Figure 29. North America Oral Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn 55
Figure 30. North America Oral Antibiotics Market: Other Mechanisms, 2019-2030, $ mn 56
Figure 31. Breakdown of North America Oral Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue 58
Figure 32. North America Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%) 58
Figure 33. North America Oral Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn 59
Figure 34. North America Oral Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn 60
Figure 35. North America Oral Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn 61
Figure 36. Breakdown of North America Oral Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue 63
Figure 37. North America Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%) 63
Figure 38. North America Oral Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn 64
Figure 39. North America Oral Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn 65
Figure 40. Breakdown of North America Oral Antibiotics Market by Application, 2019-2030, % of Revenue 67
Figure 41. North America Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 67
Figure 42. North America Oral Antibiotics Market: Urinary Tract Infections (UTIS), 2019-2030, $ mn 68
Figure 43. North America Oral Antibiotics Market: Dental Infections, 2019-2030, $ mn 69
Figure 44. North America Oral Antibiotics Market: Monotherapies for Dental Infections, 2019-2030, $ mn 70
Figure 45. North America Oral Antibiotics Market: Combined Therapies for Dental Infections, 2019-2030, $ mn 71
Figure 46. North America Oral Antibiotics Market: Respiratory Tract Infections (RTIS), 2019-2030, $ mn 72
Figure 47. North America Oral Antibiotics Market: Upper Respiratory Tract Infections (URTI), 2019-2030, $ mn 73
Figure 48. North America Oral Antibiotics Market: Lower Respiratory Tract Infections (LRTIs), 2019-2030, $ mn 74
Figure 49. North America Oral Antibiotics Market: Other Applications, 2019-2030, $ mn 75
Figure 50. Breakdown of North America Oral Antibiotics Market by Drug Type, 2019-2030, % of Revenue 76
Figure 51. North America Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%) 77
Figure 52. North America Oral Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn 78
Figure 53. North America Oral Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn 79
Figure 54. Breakdown of North America Oral Antibiotics Market by Country, 2019 and 2030, % of Revenue 81
Figure 55. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 82
Figure 56. U.S. Oral Antibiotics Market, 2019-2030, $ bn 84
Figure 57. Rising Incidence of Infectious Disease in U.S. 84
Figure 58. Canada Oral Antibiotics Market, 2019-2030, $ bn 87
Figure 59. Oral Antibiotics Market in Mexico, 2015-2030, $ bn 89
Figure 60. Growth Stage of North America Oral Antibiotics Industry over the Forecast Period 91



Logo

North America Oral Antibiotics Market Outlook, 2030

Contact usWe are friendly and approachable, give us a call.